Capricor Therapeutics (NASDAQ:CAPR) filed to sell 2.8M shares of common stock for holders. This prospectus is not an offer to sell. Filing More on Capricor Therapeutics Capricor: DMD Treatment Focus ...
On Thursday, CDW common stock (CDW) stock saw a decline, ending the day at $221.69 which represents a decrease of $-4.01 or -1.78% from the prior close of $225.7. The stock opened at $223.88 and ...
Piper Sandler and Oppenheimer & Co. are acting as the joint book-running managers for the public offering. The Company intends to use the net proceeds from this offering on the continued development ...